Hims & Hers Health Inc (HIMS) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Hims & Hers Health’s ability to scale a technology‑enabled musculoskeletal platform profitably, positioning it as a fast‑growing leader in digital health and setting a high bar for SaaS‑style health‑care companies.

Key Takeaways

• Q4 revenue $171M, 46% YoY growth.
• Full-year revenue $588M, 51% growth, beating guidance.
• Gross margin 85% Q4, 83% FY, AI-driven efficiency.
• Free cash flow $62M Q4, 36% margin.
• Contracted lives 24.6M, 24% increase year‑over‑year.

Pulse Analysis

Hims & Hers Health’s Q4 earnings underscore a rare blend of high‑growth and strong cash generation in the digital health space. Revenue surged 46% YoY to $171 million, propelling full‑year sales past the $500 million threshold with a 51% increase. The company’s operating margin climbed to 28% in the quarter, while free cash flow margin topped 36%, delivering a Rule‑of‑40 score above 80—far exceeding the industry benchmark. This financial robustness, coupled with a $665 million share repurchase that outpaced the board’s $250 million cap, signals confidence in the firm’s capital efficiency and its ability to return value to shareholders.

A cornerstone of Hims & Hers Health’s performance is its AI‑powered care platform. The rollout of Robin, an AI care assistant, earned a 92% positive member rating and accelerated response times, while AI‑enhanced workflows cut asynchronous session times by 28% and allowed the company to serve 47% more members without expanding the care team. These efficiencies lifted gross margins to 85% in Q4 and supported a 60% reduction in imaging visits for chronic back‑pain participants, reinforcing the clinical credibility of its digital musculoskeletal solutions. The integration of devices like Enso further boosts engagement, driving higher therapy adherence and reinforcing the platform’s data‑driven value proposition.

Looking ahead, the firm’s addressable market expands as contracted lives rose to 24.6 million, with notable gains in fully insured Medicare Advantage and federal employee programs. The Hinge Select network, now available to several hundred thousand eligible lives, promises to curb surgical interventions and lower low‑value spend, though revenue impact is expected post‑2027. Management’s 2026 outlook of $732‑$742 million revenue and a 21% operating margin reflects confidence in scaling AI deployments and deepening enterprise partnerships, positioning Hims & Hers Health as a durable competitor in the evolving tele‑health and musculoskeletal care landscape.